Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine

Developed for: fallopian tube clear cell adenocarcinoma · fallopian tube endometrioid tumor · fallopian tube mucinous tumor · fallopian tube transitional cell carcinoma · ovarian clear cell cystadenocarcinoma · ovarian endometrioid adenocarcinoma · ovarian mucinous cystadenocarcinoma · ovarian seromucinous carcinoma
+4 more
· ovarian serous cystadenocarcinoma · ovarian transitional cell carcinoma · primary peritoneal serous adenocarcinoma · undifferentiated ovarian carcinoma
Investigated by: Mayo Clinic · National Cancer Institute (NCI)

today NCT02111941 · Ph 0

20142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 0	NCT02111941	Apr 2014 → Jul 2021	fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid tumor, fallopian tube mucinous tumor, fallopian tube transitional cell carcinoma +8	Mayo Clinic	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02111941 ↗
Action	Deplete	“kill tumor cells” NCT02111941 ↗
Modality	Vaccine	“vaccine therapy” NCT02111941 ↗